The stock of BriaCell Therapeutics Corp (NASDAQ: BCTX) has increased by 21.04 when compared to last closing price of 0.60. Despite this, the company has experienced a 22.52% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-21 that PHILADELPHIA and VANCOUVER, British Columbia, Nov. 21, 2024 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) a clinical-stage biotech company that develops novel immunotherapies to transform cancer care, announces that the first patient was dosed in its Phase 1/2 study (ClinicalTrials.gov identifier: NCT06471673) to evaluate the safety and efficacy of Bria-OTS™, BriaCell’s personalized next generation immunotherapy. The study will investigate Bria-OTS™ alone and in combination with immune check point inhibitor tislelizumab® (manufactured and supplied by BeiGene, Ltd.) for the treatment of metastatic breast cancer. Bria-OTS™ is an enhanced form of Bria-IMT™, currently in pivotal Phase 3 study for metastatic breast cancer.
Is It Worth Investing in BriaCell Therapeutics Corp (NASDAQ: BCTX) Right Now?
BCTX has 36-month beta value of 1.37. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BCTX is 32.50M, and currently, short sellers hold a 2.24% ratio of that float. The average trading volume of BCTX on November 21, 2024 was 4.91M shares.
BCTX’s Market Performance
The stock of BriaCell Therapeutics Corp (BCTX) has seen a 22.52% increase in the past week, with a -20.76% drop in the past month, and a -15.71% fall in the past quarter. The volatility ratio for the week is 6.94%, and the volatility levels for the past 30 days are at 8.74% for BCTX. The simple moving average for the past 20 days is 2.81% for BCTX’s stock, with a -52.60% simple moving average for the past 200 days.
Analysts’ Opinion of BCTX
Many brokerage firms have already submitted their reports for BCTX stocks, with H.C. Wainwright repeating the rating for BCTX by listing it as a “Buy.” The predicted price for BCTX in the upcoming period, according to H.C. Wainwright is $25 based on the research report published on February 14, 2022 of the previous year 2022.
BCTX Trading at -6.59% from the 50-Day Moving Average
After a stumble in the market that brought BCTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.79% of loss for the given period.
Volatility was left at 8.74%, however, over the last 30 days, the volatility rate increased by 6.94%, as shares sank -20.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.52% upper at present.
During the last 5 trading sessions, BCTX rose by +19.14%, which changed the moving average for the period of 200-days by -81.98% in comparison to the 20-day moving average, which settled at $0.7081. In addition, BriaCell Therapeutics Corp saw -87.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCTX starting from Lustig Marc, who purchase 902,935 shares at the price of $2.21 back on May 14 ’24. After this action, Lustig Marc now owns 2,542,935 shares of BriaCell Therapeutics Corp, valued at $2,000,001 using the latest closing price.
Stock Fundamentals for BCTX
Current profitability levels for the company are sitting at:
- -1466.65 for the present operating margin
- 0.5 for the gross margin
The net margin for BriaCell Therapeutics Corp stands at -213.79. The total capital return value is set at 20.93. Equity return is now at value -202.12, with -29.01 for asset returns.
Currently, EBITDA for the company is -4.77 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 1127.22. The receivables turnover for the company is 0.02for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.49.
Conclusion
To put it simply, BriaCell Therapeutics Corp (BCTX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
